MAPK8 and colorectal carcinoma: In summary, our study demonstrates that menadione, an FDA-approved compound, exerts potent anti-tumor effects in CRC cells by simultaneously inducing necroptosis, apoptosis, and autophagy, which is mediated through activation of MAPK8.